Wednesday, 8 October 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 08 October 2025
News

PBAC hopefuls score TGA wins

Posted 7 October 2025 AM

One new brand and two new forms of previously approved medicines have hit the ARTG, with the sponsors already on the agenda for the PBAC's November meeting.

Roche has a new form of 5q spinal muscular atrophy drug Evrysdi approved, as a tablet. It's currently listed as a powder for oral solution, and the tablet form adds convenience some people may desire, such as being able to be stored at room temperature instead of refrigerated. It can be taken whole or mixed with non-chlorinated water.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (29)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (2)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.